CD79A and nasopharyngeal carcinoma: Although there is so far no evidence from randomized clinical trial to support the screening of NPC using the EBV serological markers [52], in fact, it is very popular to conduct NPC screening since the 1970's in the southern China [43]–[44], [53], and the two markers of VCA/IgA and EA/IgA are most commonly used.